Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) PT at $7.75

Bausch Health Companies Inc. (NYSE:BHC) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.

Several research analysts have commented on the company. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Scotiabank cut their target price on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research note on Friday, August 2nd. Evercore ISI raised Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Truist Financial dropped their price objective on shares of Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Finally, Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 1st.

Bausch Health Companies Trading Down 2.0 %

NYSE:BHC opened at $9.50 on Friday. The firm has a market capitalization of $3.49 billion, a PE ratio of -19.79 and a beta of 0.74. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The firm’s fifty day simple moving average is $7.76 and its 200 day simple moving average is $7.08.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the business posted $1.03 earnings per share. The firm’s revenue was up 12.2% compared to the same quarter last year. As a group, analysts anticipate that Bausch Health Companies will post 3.73 EPS for the current fiscal year.

Insider Transactions at Bausch Health Companies

In related news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the transaction, the executive vice president now directly owns 435,198 shares of the company’s stock, valued at $2,702,579.58. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 8.12% of the company’s stock.

Institutional Trading of Bausch Health Companies

A number of hedge funds and other institutional investors have recently modified their holdings of BHC. Headlands Technologies LLC acquired a new position in Bausch Health Companies during the 2nd quarter worth $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies during the second quarter valued at $71,000. Certuity LLC bought a new position in Bausch Health Companies in the second quarter valued at about $75,000. Bfsg LLC increased its position in Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management bought a new stake in Bausch Health Companies during the 2nd quarter worth about $87,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.